Clinical manifestations are complex and often involve multiple systems. Early identification and standardization of clinical treatments are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical manifestations, imaging inspections, laboratory tests and pathological activation.
The platform can assist in matching authoritative experts and teams at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune disorders that were previously difficult to treat have been significantly improved. Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the course of treatment.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of lupus antigens. The platform serves China International Medical Service System, a team of domestic and foreign experts with authority in the field of autoimmune and rheumatic immunity, to provide the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.